• Home
  • Search Results

Research Studies

UNC-Chapel Hill Lineberger Comprehensive Cancer Center

268 studies match your search

IDH-Wildtype Glioblastoma Treatment Study

In this study, we will find out if a new experimental pill called ropidoxuridine can help improve the treatment of a brain cancer called IDH-Wildtype Glioblastoma. We want to see how well it works when used with radiation therapy.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Brain and Other Nervous System)
Open

Relapsed Peripheral T-cell Lymphoma Treatment Study

Do you have relapsed peripheral T-cell lymphoma (PTCL)? Has your cancer not gotten better with other treatments, or were those treatments stopped because of bad side effects? If so, you might be able to join a study to see if a new drug called Soquelitinib (also known as CPI-818) can treat PTCL better.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Lymphoma)

A Phase 1b Study of AMG509 in Subjects w/ High-risk Biochemical Recurrence of Prostate Cancer

This study is being carried out to learn more about administration of xaluritamig in people with high-risk biochemical recurrence (BCR) or sometimes referred to as nonmetastatic castration-sensitive prostate cancer (nmCSPC) after receiving definitive (primary) treatment.

Age & Gender
  • 18 years ~ 99 years
  • Male
Study Interest
  • Cancer (Prostate, Phase 1 Trials (all cancers))
  • Rare Diseases
  • Men's Health
Open

Advanced Melanoma Treatment Study

Do you have advanced melanoma that has progressed on treatment? Do you have a tumor longer than 1cm in length? If so, you might be able to take part in a study that compares a study treatment (Vusolimogene Oderparepvec and Nivolumab) with your physician's choice of standard of care treatment. Compensation provided.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Melanoma)
Open

PUMA-ALI-1201: A PHASE 2 STUDY OF ALISERTIB IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH HR+, HER2-NEGATIVE RECURRENT OR METASTATIC BREAST CANCER

Have you been diagnosed with hormone receptor (HR+) and human epidermal growth factor receptor 2 (HER2)-negative recurrent or metastatic breast cancer? If so, you may be eligible for a clinical trial investigating the combination of endocrine therapy with alisertib.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Open

Rehabilitation outcomes study

Have you been diagnosed with cancer. If so, you may be able to take part in a research study looking to improve cancer care for patients whose treatment outcomes have led to challenges in their quality of life.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 19 more)
Open

Basal-like PDAC treated with Gemcitabine, Erlotinib and nab-paclitaxel (PANGEA).

Are you a patient with advanced basal-like pancreatic adenocarcinoma? If so this could the a Trial for you to as this is a Phase I/II trial is to evaluate the safety, efficacy and tolerability of low-dose EGFR inhibitors in combination with bi-weekly gemcitabine/nab-paclitaxel (GnP) in subjects with basal tumors

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Pancreatic)
Open

First in Human Study of IMGN151 in adut patients with Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers.

Do you have Recurrent endometrial cancer,Recurrent, high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer that has progressed during or after standard treatments? If so, you may be able to take part in a research study looking at the safety of giving a treatment of test drug IMGN151-1001 to patients with these types of cancer

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Uterine (endometrial), Ovarian)

Venetoclax, MLN9708 and Dexamethasone for Relapsed or Refractory Light Chain Amyloidosis

This study is being done to answer the following question: What is the dose of venetoclax, MLN9708 (ixazomib citrate), and dexamethasone in combination that can be safely and tolerably taken by patients with amyloidosis? We are doing this study because we want to find out if this approach is better or worse than the usual approach for amyloidosis. The usual approach is defined as care most people get for amyloidosis.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Other Cancers)
Open

A PHASE 1/2A, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY, AND PHARMACOKINETICS OF REGN10597 (ANTI PD-1-IL2RA-IL2 FUSION PROTEIN) IN PATIENTS WITH ADVANCED SOLID ORGAN MALIGNANCIES

Do you have kidney or bladder cancer. You may be able to participate in a research study to find out if the investigational drug REGN10597 is safe, tolerable, and effective in treating kidney and bladder cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Kidney)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research